HK1220625A1 - 提高遞送治療性化合物到眼睛的方法 - Google Patents
提高遞送治療性化合物到眼睛的方法Info
- Publication number
- HK1220625A1 HK1220625A1 HK16108714.0A HK16108714A HK1220625A1 HK 1220625 A1 HK1220625 A1 HK 1220625A1 HK 16108714 A HK16108714 A HK 16108714A HK 1220625 A1 HK1220625 A1 HK 1220625A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- eye
- therapeutic compounds
- enhancing delivery
- enhancing
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361785015P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/026224 WO2014160281A2 (en) | 2013-03-14 | 2014-03-13 | Method of enhancing delivery of therapeutic compounds to the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1220625A1 true HK1220625A1 (zh) | 2017-05-12 |
Family
ID=50687629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16108714.0A HK1220625A1 (zh) | 2013-03-14 | 2016-07-20 | 提高遞送治療性化合物到眼睛的方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9730888B2 (zh) |
EP (1) | EP2968476B1 (zh) |
JP (3) | JP6483083B2 (zh) |
AU (2) | AU2014243925B2 (zh) |
CA (1) | CA2903545C (zh) |
HK (1) | HK1220625A1 (zh) |
WO (1) | WO2014160281A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403260D0 (en) | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
MX2019002321A (es) * | 2016-08-29 | 2019-10-21 | Univ Wayne State | Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas. |
JP6757024B2 (ja) * | 2016-09-02 | 2020-09-16 | 学校法人慶應義塾 | 視覚機能再生剤又は視覚機能低下予防剤 |
WO2018128412A1 (ko) * | 2017-01-06 | 2018-07-12 | 경북대학교 산학협력단 | 혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도 |
JP6954995B2 (ja) * | 2017-03-28 | 2021-10-27 | 森永乳業株式会社 | 非コラーゲン性糖タンパク質分解用組成物 |
US11771741B2 (en) | 2019-09-13 | 2023-10-03 | Restore Vision Inc. | Nucleic acid construct that encodes chimeric rhodopsin |
CN116648265A (zh) * | 2020-09-17 | 2023-08-25 | 锐视维公司 | 用于治疗或预防与内质网应激或全反式视黄醛相关的疾病、障碍或症状、或者用于保护视网膜厚度、或者用于抑制视网膜厚度的萎缩或萎缩进展的组合物 |
CN113355309B (zh) * | 2021-08-10 | 2021-11-05 | 迈威(上海)生物科技股份有限公司 | 重组截短型人纤维蛋白溶酶制备工艺 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU775245B2 (en) | 1998-09-17 | 2004-07-22 | Catholic University Nijmegen | Methods for treatment of degenerative retinal diseases |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
WO2007005856A1 (en) * | 2005-06-30 | 2007-01-11 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment |
US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
CN101484005A (zh) | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
WO2009067407A2 (en) * | 2007-11-19 | 2009-05-28 | Bausch & Lomb Incorporated | Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof |
RU2564131C2 (ru) * | 2009-07-10 | 2015-09-27 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
ES2534911T3 (es) * | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
US10947281B2 (en) | 2012-03-05 | 2021-03-16 | Wayne State University | Identification of channelrhodopsin-2 (ChR2) mutations and methods of use |
-
2014
- 2014-03-13 CA CA2903545A patent/CA2903545C/en active Active
- 2014-03-13 US US14/777,420 patent/US9730888B2/en active Active
- 2014-03-13 AU AU2014243925A patent/AU2014243925B2/en active Active
- 2014-03-13 EP EP14723170.8A patent/EP2968476B1/en active Active
- 2014-03-13 WO PCT/US2014/026224 patent/WO2014160281A2/en active Application Filing
- 2014-03-13 JP JP2016502078A patent/JP6483083B2/ja active Active
-
2016
- 2016-07-20 HK HK16108714.0A patent/HK1220625A1/zh unknown
-
2017
- 2017-08-14 US US15/676,268 patent/US20180064640A1/en not_active Abandoned
-
2018
- 2018-12-05 JP JP2018228150A patent/JP2019055980A/ja active Pending
-
2019
- 2019-03-04 AU AU2019201474A patent/AU2019201474A1/en not_active Abandoned
- 2019-10-04 US US16/593,302 patent/US20200268647A1/en not_active Abandoned
-
2020
- 2020-11-12 JP JP2020188684A patent/JP2021038240A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US9730888B2 (en) | 2017-08-15 |
AU2014243925B2 (en) | 2018-12-06 |
CA2903545A1 (en) | 2014-10-02 |
AU2019201474A1 (en) | 2019-03-28 |
US20180064640A1 (en) | 2018-03-08 |
EP2968476B1 (en) | 2021-05-05 |
JP6483083B2 (ja) | 2019-03-13 |
JP2019055980A (ja) | 2019-04-11 |
US20200268647A1 (en) | 2020-08-27 |
JP2016519063A (ja) | 2016-06-30 |
WO2014160281A3 (en) | 2015-04-09 |
CA2903545C (en) | 2022-09-06 |
EP2968476A2 (en) | 2016-01-20 |
AU2014243925A1 (en) | 2015-10-08 |
US20160038409A1 (en) | 2016-02-11 |
JP2021038240A (ja) | 2021-03-11 |
WO2014160281A2 (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287516A (en) | Medicinal uses of empagliflozin | |
HRP20190101T1 (hr) | Terapeutske uporabe empagliflozina | |
HRP20181296T1 (hr) | Novi spojevi za suzbijanje člankonožaca | |
HK1213818A1 (zh) | 依帕列淨的治療用途 | |
GB201321729D0 (en) | Therapeutic agents | |
GB201321728D0 (en) | Therapeutic agents | |
GB201321730D0 (en) | Therapeutic agents | |
HK1220625A1 (zh) | 提高遞送治療性化合物到眼睛的方法 | |
RS58097B1 (sr) | Terapeutske primene empagliflozina | |
EP2968321A4 (en) | COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES | |
GB201321742D0 (en) | Therapeutic agents | |
GB201308440D0 (en) | Therapeutic | |
IL243637B (en) | PPAR-sparing compounds for the treatment of metabolic diseases | |
GB201318668D0 (en) | Sonosensitive therapeutic | |
PT2948129T (pt) | Compostos terapêuticos | |
GB201313356D0 (en) | Therapeutic Intervention | |
GB201320905D0 (en) | Therapeutic compounds | |
EP2979695A4 (en) | THERAPEUTIC AGENT AGAINST EYE DISEASES | |
GB201314286D0 (en) | Therapeutic Compounds | |
GB201312499D0 (en) | Therapeutic compounds | |
EP2996684A4 (en) | THERAPEUTIC PROCEDURES | |
GB201314397D0 (en) | Therapeutic Compounds | |
GB201311169D0 (en) | Therapeutic compounds | |
EP2958932A4 (en) | THERAPEUTIC AGENTS | |
GB201321504D0 (en) | Novel analgesic therapy |